Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer.

Saved in:
Bibliographic Details
Title: Impact of pathologic re-review on grade, clinical stage, and risk stratification for patients with nonmuscle invasive bladder cancer.
Authors: Campbell RA; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Wood A; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Michael PD; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Shin D; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Pramod N; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Haywood SC; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Eltemamy M; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Weight C; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Haber GP; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Lee B; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Myles J; Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH., McKenney J; Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH., Nguyen J; Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH., Williamson SR; Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH., Przybycin C; Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH., Alaghehbandan R; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH., Almassi N; Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH. Electronic address: almassn2@ccf.org.
Source: Urologic oncology [Urol Oncol] 2024 Nov; Vol. 42 (11), pp. 372.e21-372.e27. Date of Electronic Publication: 2024 Jun 15.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 9805460 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2496 (Electronic) Linking ISSN: 10781439 NLM ISO Abbreviation: Urol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2496
DOI:10.1016/j.urolonc.2024.05.020